STOCK TITAN

NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

NuCana plc (NASDAQ: NCNA) announced financial results for Q1 2022, reporting a net loss of £8.4 million, an improvement from £9.8 million in Q1 2021. Cash and equivalents stood at £52.6 million as of March 31, 2022. The company initiated a randomized Phase 2 study of NUC-3373 for colorectal cancer and a Phase 1b/2 study in combination with PD-1 inhibitors. The first patients have been enrolled in the Phase 2 study of NUC-7738. NuCana is well-capitalized with a projected cash runway into 2025, indicating potential for significant clinical milestones.

Positive
  • Improved net loss of £8.4 million for Q1 2022 compared to £9.8 million in Q1 2021.
  • Cash and cash equivalents of £52.6 million as of March 31, 2022.
  • Initiation of randomized Phase 2 study of NUC-3373 for colorectal cancer.
  • First patients enrolled in Phase 2 study of NUC-7738, indicating progress in clinical development.
  • Anticipated cash runway extending into 2025, supporting ongoing clinical programs.
Negative
  • Net loss of £8.4 million indicates ongoing financial challenges despite improvement.
  • Decrease in cash and cash equivalents from £60.3 million as of December 31, 2021.

Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer

Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other Agents, Including PD-1 Inhibitors, in Patients with Solid Tumors

First Patients Enrolled in Phase 2 Study of NUC-7738

Multiple Data Readouts in 2022

Well Capitalized with Anticipated Cash Runway into 2025

EDINBURGH, United Kingdom, June 02, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

As of March 31, 2022, NuCana had cash and cash equivalents of £52.6 million compared to £60.3 million as of December 31, 2021. NuCana continues to advance its various clinical programs and reported a net loss of £8.4 million for the quarter ended March 31, 2022, as compared to a net loss of £9.8 million for the quarter ended March 31, 2021. Basic and diluted loss per share was £0.16 for the quarter ended March 31, 2022, as compared to £0.19 per share for quarter ended March 31, 2021.

“We are excited about the optimized development plan we recently announced for NUC-3373 in colorectal cancer and have initiated the randomized Phase 2 study, NuTide:323, in second-line patients”, said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “We are also pleased to have initiated the NuTide:303 Phase 1b/2 study of NUC-3373 in combination with other agents, including PD-1 inhibitors, for the treatment of patients with solid tumors. In addition, we have enrolled the first patients into the Phase 2 part of the NuTide:701 study of NUC-7738. We look forward to providing numerous data updates throughout 2022 for both NUC-3373 and NUC-7738.”

Mr. Griffith continued: “Positive data that we have previously announced for NUC-3373 and NUC-7738 have demonstrated our ProTides’ potential to provide cancer patients with more efficacious and safer treatment options. These data continue to demonstrate our ProTides’ encouraging anti-cancer activity and favorable safety profiles and pharmacokinetic properties.”

Mr. Griffith concluded: “We have an anticipated cash runway which we expect will extend into 2025 and through many key milestones for both NUC-3373 and NUC-7738. We look forward to progressing towards our goal of significantly improving treatment options for patients with cancer.”

Anticipated 2022 Milestones

  • NUC-3373 (a ProTide transformation of 5-FU)

         In 2022, NuCana expects to:

    • Commence enrollment in the randomized, controlled Phase 2 (NuTide:323) study of NUC-3373 in combination with other agents for the second-line treatment of patients with colorectal cancer;
    • Commence enrollment in the Phase 1b/2 (NuTide:303) modular study of NUC-3373 in combination with other agents, including PD-1 inhibitors, in patients with solid tumors to identify additional indications for development;
    • Expand the Phase 1b/2 (NuTide:302) study of NUC-3373 in second-line colorectal cancer patients, and evaluate NUC-3373-based regimens in combination with bevacizumab;
    • Announce data from the Phase 1b/2 (NuTide:302) study of NUC-3373 combined with leucovorin, irinotecan and bevacizumab in patients with colorectal cancer; and
    • Announce data from the Phase 1b/2 (NuTide:303) modular study of NUC-3373 in combination with other agents in patients with solid tumors to identify additional indications for development.
  • NUC-7738 (a ProTide transformation of 3’-deoxyadenosine)

         In 2022, NuCana expects to:

    • Announce data from the Phase 1 part of the NuTide:701 study of NUC-7738 in patients with solid tumors; and
    • Announce data from the Phase 2 part of the NuTide:701 study of NUC-7738 in patients with solid tumors.

About NuCana
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent and is in a Phase 1b/2 study in patients with metastatic colorectal cancer. NUC-7738, is a transformation of a novel anti-cancer nucleoside analog (3’-deoxyadenosine) and is in a Phase 1/2 study for patients with advanced solid tumors.

Forward-Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; and the sufficiency of the Company’s current cash, cash equivalents and marketable securities to fund its planned operations into 2025. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on April 27, 2022, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

 
Unaudited Condensed Consolidated Statements of Operations
 
  For the Three Months Ended
March 31,
  2022 2021
  (in thousands, except per share data)
  £
 £
Research and development expenses (9,446) (8,706)
Administrative expenses (2,152) (2,104)
Net foreign exchange gains (losses) 1,131  (677)
Operating loss (10,467) (11,487)
Finance income 31  24 
Loss before tax (10,436) (11,463)
Income tax credit 2,033  1,702 
Loss for the period (8,403) (9,761)
       
Basic and diluted loss per share (0.16) (0.19)


 
Unaudited Condensed Consolidated Statements of Financial Position
 
  March 31, 2022
 December 31, 2021
  (in thousands)
  £
 £
Assets      
Non-current assets      
Intangible assets 2,505  2,410 
Property, plant and equipment 727  851 
Deferred tax asset 68  60 
Other non-current assets 2,556  2,540 
  5,856  5,861 
Current assets      
Prepayments, accrued income and other receivables 3,790  4,161 
Current income tax receivable 9,215  7,188 
Cash and cash equivalents 52,561  60,264 
  65,566  71,613 
Total assets 71,422  77,474 
       
Equity and liabilities      
Capital and reserves      
Share capital and share premium 143,138  143,137 
Other reserves 73,481  72,137 
Accumulated deficit (157,901) (149,726)
Total equity attributable to equity holders of the Company 58,718  65,548 
       
Non-current liabilities      
Provisions 46  46 
Lease liabilities 141  164 
  187  210 
Current liabilities      
Trade payables 2,699  1,829 
Payroll taxes and social security 714  170 
Accrued expenditure 8,945  9,510 
Lease liabilities 159  207 
  12,517  11,716 
Total liabilities 12,704  11,926 
Total equity and liabilities 71,422  77,474 
       


 
Unaudited Condensed Consolidated Statements of Cash Flows
 
 For the Three Months Ended
March 31,
 2022 2021
 (in thousands)
 £
 £
Cash flows from operating activities     
Loss for the period(8,403) (9,761)
Adjustments for:     
Income tax credit(2,033) (1,702)
Amortization and depreciation197  222 
Finance income(32) (24)
Interest expense on lease liabilities3  6 
Share-based payments1,575  1,795 
Net foreign exchange (gains) losses(1,149) 664 
 (9,842) (8,800)
Movements in working capital:     
Decrease (increase) in prepayments, accrued income and other receivables390  (191)
Increase in trade payables870  1,285 
Decrease in payroll taxes, social security and accrued expenditure(38) (368)
Movements in working capital1,222  726 
Cash used in operations(8,620) (8,074)
Net income tax received-  - 
Net cash used in operating activities(8,620) (8,074)
Cash flows from investing activities     
Interest received31  24 
Payments for property, plant and equipment-  (4)
Payments for intangible assets(166) (138)
Net cash used in investing activities(135) (118)
Cash flows from financing activities     
Payments for lease liabilities(75) (74)
Proceeds from issue of share capital1  198 
Net cash (used in) from financing activities(74) 124 
Net decrease in cash and cash equivalents(8,829) (8,068)
Cash and cash equivalents at beginning of period60,264  87,356 
      
Effect of exchange rate changes on cash and cash equivalents1,126  (663)
Cash and cash equivalents at end of period52,561  78,625 
      

For more information, please contact:

NuCana plc
Hugh S. Griffith
Chief Executive Officer
+44 131 357 1111
info@nucana.com

Westwicke, an ICR Company
Chris Brinzey
+1 339-970-2843
chris.brinzey@westwicke.com

RooneyPartners
Marion Janic
+1 212-223-4017
mjanic@rooneyco.com 


FAQ

What were NuCana's financial results for Q1 2022?

NuCana reported a net loss of £8.4 million for Q1 2022, an improvement from £9.8 million in Q1 2021.

What is NUC-3373 and what studies are ongoing for it?

NUC-3373 is a ProTide transformation of 5-FU, with ongoing studies including a randomized Phase 2 study for colorectal cancer and a Phase 1b/2 study in combination with PD-1 inhibitors.

What is the cash position of NuCana as of March 31, 2022?

As of March 31, 2022, NuCana had cash and cash equivalents of £52.6 million.

What future milestones does NuCana anticipate in 2022?

NuCana anticipates several data readouts and the continuation of ongoing studies for both NUC-3373 and NUC-7738 throughout 2022.

How does the net loss for Q1 2022 compare to the previous year?

The net loss for Q1 2022 was £8.4 million, which is an improvement compared to £9.8 million in Q1 2021.

NuCana plc American Depositary Share

NASDAQ:NCNA

NCNA Rankings

NCNA Latest News

NCNA Stock Data

5.57M
3.93M
0.53%
11.82%
2.83%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
GAITHERSBURG